IBD Evidence

Kura

Bioloġiċi u terapiji avvanzati mqabbla

Għall-ewwel darba, il-mistoqsija komparattiva — liema mediċina, mhux jekk mediċina — għandha risposti meta-analitiċi.

Aġġornat 2 min read 40 ċitazzjonijiet Saħħa tal-evidenza 5/5

Snare għall-endoskopija tal-wajer użat għall-polipektomija tal-ġiżir u tal-kolon
Gilo1969 · CC BY-SA 3.0 · Wikimedia Commons

X'ħareġ ġdid

Għal għaxar snin, l-evidenza kienet bejn id-droga u l-placebo, li qalet lill-kliniċi li l-bioloġiċi jaħdmu u xejn dwar liema għandhom jagħżlu. L-analiżi meta-netwerk ħarġet b'dan billi tuża komparaturi kondiviżi biex tordna t-terapiji b'mod indirett [1][4].

Il-konsegwenza prattika hi li l-għażla ta' l-ewwel linja issa tista' tiġi raġunata minflok tkun predefinita, u d-differenzi bejn l-aġenti fuq l-induzzjoni kontra l-manteniment, u fuq l-effiċjenza kontra s-sigurtà, huma viżibbli.

Efficacia komparattiva ta' terapiji avvanzati

Il-klassi

Klassi ta' terapija avvanzata fl-IBD
KlassMezzanismuNota
Anti-TNFJibblil il-fattur ta' neqsin tat-tumuri alfaL-aktar rekord twil; l-immunoġeniċità hija l-prinċipali limitazzjoni
Anti-integrinBlokka t-traffikar tal-lewkoċiti lejn il-ġutSelettiv għall-istonku, għalhekk sigurtà sistemika favorevoli
Anti-IL-12/23 u anti-IL-23Jibblil is-sinjali tal-interleukinProfil ta' effikaċja u sigurtà qawwi f'komparazzjonijiet riċenti
Inibituri JAKMolekula żgħira, sinjalizzazzjoni intraċellulariOrali u rapidu; twissijiet dwar il-qalb u t-thrombosi
Modulatori S1PIssekwestra l-limfociti fil-limfa nodiOrali; data ġodda, inqas ta' żmien twil

Tratta għall-mira, mhux għall-sintomi

L-ikbar bidla fl-immaniġġ ta' IBD hija li s-sintomi huma proxy ħażin għall-infjammazzjoni. In-nies iħossu tajjeb bi infjammazzjoni attiva u iħossu ħażin fil-remissjoni. Il-linji gwida Ewropej attwali għalhekk jiffokaw fuq markaturi oġġettivi — calprotectin f'faċes, fejqan endoskopiku — minflok kif ir-rieda tal-pazjent tiddeskrivi l-ħoss.

Dan huwa wkoll l-għażla għall-mistoqsija dietetika mqajma fuq il-paġna tad-dieta: intervent li jtejjeb is-sintomi mingħajr ma jtejjeb il-markaturi oġġettivi ma ġiex trattat id-disa.]

Meta waħda ma tkunx biżżejjed

Il-bioloġija doppja jew it-terapija kombinata ta' molekuli żgħar ġiet evalwata għal mard refrattarju [3]. Għadha deċiżjoni speċjalista bi bażi ta' evidenza limitata, u hawnhekk ix-xogħol ta' ċellula waħda li jiddeskrivi l-heteroġeneità tar-risposta [2] huwa l-iktar probabbli li jbiddel il-prattika — billi jippredġi liema mekaniżmu għandu jiġi mfittxielu f'patient partikolari minflok jiskoprih permezz ta' falliment sekondarju.

Veduta tal-ġenb tal-bini tal-farmacia tal-istazzjon f'Bautzen, il-Ġermanja
Fiver, der Hellseher · CC BY-SA 4.0 · Wikimedia Commons

Mistoqsijiet komuni

Liema bioloġiku huwa l-aħjar?
L-analiżi tal-meta-netwerk issa tpoġġihom fil-klassifikazzjoni [1][4], u l-għażla t-tajba tiddependi fuq il-lok tal-marda, is-severità, il-karatteristiċi extraintestinals u r-riskju personali tiegħek.
Nista' nħalliha waħda meta nkun fil-remissjoni?
Il-irtirar iġġib riskju sostanzjali ta' riġress. Huwa deċiżjoni li tagħmel mal-tim tiegħek, ibbażata fuq markaturi oġġettivi minflok kif tħossok.
Huma l-bioloġika perikolużi?
Huma jġorru riskji reali, prinċipalment infezzjoni. Infezzjoni mhux trattata wkoll ġġorr riskju, u l-paragun huwa bejn żewġ riskji minflok kontra żero.
X'jintuża l-calprotectin?
Markatur tal-ħmieġ ta' infjamazzjoni intestinali. Huwa kif "ttratta biex tilħaq l-għan" fil-fatt jiġi mmonitorjat.
Il-provi li hemm wara din il-paġna Bar imwaħħal li juri l-kompożizzjoni tal-20 pubblikazzjoni mniżżla f'din il-paġna skont it-tip ta' studju. 24meta-analysis (24)
20 pubblikazzjonijiet, 2015–2025. Dan huwa bażi b'mod osservazzjonali. Huwa jista' jistabbilixxi li affarijiet iseħħu flimkien; ma jistax jiddetermina liema waħda tikkawża l-oħra. Sors: il-lista ta' ċitazzjonijiet ta' din il-paġna, hawn taħt.

Referenzi

Kull ċitazzjoni hawn taħt tgħaqqad mal-record oriġinali peer-reviewed fuq PubMed jew permezz ta' DOI. Xejn hawnhekk m'għandux ikun sostitut għal parir mediku.

  1. Dual biologics or combination therapy with small molecules in pediatric inflammatory bowel disease: a systematic review and meta-analysis Huo BL, Zhao AL, Liu W, et al. · World journal of pediatrics : WJP · 2026 · Meta-analysis DOIPubMed 42387245
  2. Phenotypic Differences in Inflammatory Bowel Diseases Across Race, Ethnicity, and Geography: A Systematic Review of 237 Population-Based Studies Halim A, Ho AHY, Wanchaitanawong W, et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2026 · Meta-analysis DOIPubMed 41577066
  3. Blood Bile Acids for Inflammatory Bowel Disease Diagnosis and Disease Activity Assessment: A Metabolomics Meta-Analysis Thu NQ, An VT, Dat LHB, et al. · Journal of proteome research · 2026 · Meta-analysis DOIPubMed 42695907
  4. Safety of advanced therapies in pregnant women with inflammatory bowel disease: a systematic review and Meta-Analysis Moraes BF, Leite GAPD, Visentini LM, et al. · Journal of Crohn's & colitis · 2026 · Meta-analysis DOIPubMed 41874976
  5. The Role of Inflammation in Infant Colic-A Systematic Review and Meta-Analysis Andersen DB, Fog J, Vestergaard MV, et al. · Acta paediatrica (Oslo, Norway : 1992) · 2026 · Meta-analysis DOIPubMed 41803938Full text
  6. S3 Guideline for the Treatment of Psoriasis vulgaris, adapted from EuroGuiDerm - part 2: Specific clinical and comorbid situations Nast A, Altenburg A, Augustin M, et al. · Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026 · Clinical guideline DOIPubMed 41641952Full text
  7. Management of paediatric ulcerative colitis, part 2: Acute severe colitis-An updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organization Assa A, Aloi M, Van Biervliet S, et al. · Journal of pediatric gastroenterology and nutrition · 2025 · Clinical guideline DOIPubMed 40528309
  8. Management of paediatric ulcerative colitis, part 1: Ambulatory care-An updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organisation Wine E, Aloi M, Van Biervliet S, et al. · Journal of pediatric gastroenterology and nutrition · 2025 · Clinical guideline DOIPubMed 40677018Full text
  9. Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on the use of Telemedicine in Inflammatory Bowel Disease Aguas Peris M, Del Hoyo Francisco J, Nos Mateu P, et al. · Gastroenterologia y hepatologia · 2025 · Clinical guideline DOIPubMed 39672505
  10. Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Crohn's Disease: 2025 AGA Evidence Synthesis Singh S, Murad MH, Yuan Y, et al. · Gastroenterology · 2025 · Meta-analysis DOIPubMed 41114682Full text
  11. AGA Living Clinical Practice Guideline on the Pharmacologic Management of Moderate-to-Severe Crohn's Disease Scott FI, Ananthakrishnan AN, Click B, et al. · Gastroenterology · 2025 · Clinical guideline DOIPubMed 41274746Full text
  12. British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025 Moran GW, Gordon M, Sinopolou V, et al. · Gut · 2025 · Clinical guideline DOIPubMed 40550582
  13. ACG Clinical Guideline Update: Ulcerative Colitis in Adults Rubin DT, Ananthakrishnan AN, Siegel CA, et al. · The American journal of gastroenterology · 2025 · Clinical guideline DOIPubMed 40701556
  14. ACG Clinical Guideline: Management of Crohn's Disease in Adults Lichtenstein GR, Loftus EV, Afzali A, et al. · The American journal of gastroenterology · 2025 · Clinical guideline DOIPubMed 40701562
  15. AGA Clinical Practice Guideline on the Management of Pouchitis and Inflammatory Pouch Disorders Barnes EL, Agrawal M, Syal G, et al. · Gastroenterology · 2024 · Clinical guideline DOIPubMed 38128971Full text
  16. AGA Clinical Practice Update on Diet and Nutritional Therapies in Patients With Inflammatory Bowel Disease: Expert Review Hashash JG, Elkins J, Lewis JD, et al. · Gastroenterology · 2024 · Clinical guideline DOIPubMed 38276922
  17. Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis Ananthakrishnan AN, Murad MH, Scott FI, et al. · Gastroenterology · 2024 · Meta-analysis DOIPubMed 39425738Full text
  18. AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis Singh S, Loftus EV Jr, Limketkai BN, et al. · Gastroenterology · 2024 · Clinical guideline DOIPubMed 39572132Full text
  19. ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment Adamina M, Minozzi S, Warusavitarne J, et al. · Journal of Crohn's & colitis · 2024 · Clinical guideline DOIPubMed 38878002
  20. Single-cell meta-analysis of inflammatory bowel disease with scIBD Nie H, Lin P, Zhang Y, et al. · Nature computational science · 2023 · Meta-analysis DOIPubMed 38177426
  21. Features of paradoxical psoriasis and risk factors in inflammatory bowel disease: A systematic review and meta-analysis Croitoru DO, Brooks SG, Nathanielsz N, et al. · Journal of the European Academy of Dermatology and Venereology : JEADV · 2023 · Meta-analysis DOIPubMed 36912825
  22. JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications Russell MD, Stovin C, Alveyn E, et al. · Annals of the rheumatic diseases · 2023 · Meta-analysis DOIPubMed 37247942Full text
  23. Altered Bioavailability and Pharmacokinetics in Crohn's Disease: Capturing Systems Parameters for PBPK to Assist with Predicting the Fate of Orally Administered Drugs Alrubia S, Mao J, Chen Y, et al. · Clinical pharmacokinetics · 2022 · Meta-analysis DOIPubMed 36056298Full text
  24. Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis Ahmed W, Galati J, Kumar A, et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022 · Meta-analysis DOIPubMed 33798711
  25. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis Lasa JS, Olivera PA, Danese S, et al. · The lancet. Gastroenterology & hepatology · 2022 · Meta-analysis DOIPubMed 34856198
  26. Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials Ben-Horin S, Novack L, Mao R, et al. · Gastroenterology · 2022 · Meta-analysis DOIPubMed 34757139
  27. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis Peyrin-Biroulet L, Arkkila P, Armuzzi A, et al. · BMC gastroenterology · 2022 · Meta-analysis DOIPubMed 35676620Full text
  28. [ESPEN guideline: Clinical nutrition in inflammatory bowel disease] Bischoff SC, Escher J, Hébuterne X, et al. · Nutricion hospitalaria · 2022 · Clinical guideline DOIPubMed 35014851
  29. Recommendations of the Spanish Working Group on Crohn's disease and Ulcerative Colitis (Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa - GETECCU) on dysplasia screening in inflammatory bowel disease patients Sicilia B, Vicente R, Arias L, et al. · Gastroenterologia y hepatologia · 2021 · Clinical guideline DOIPubMed 33592179
  30. Long-term dietary patterns are associated with pro-inflammatory and anti-inflammatory features of the gut microbiome Bolte LA, Vich Vila A, Imhann F, et al. · Gut · 2021 · Meta-analysis DOIPubMed 33811041Full text
  31. WSES-AAST guidelines: management of inflammatory bowel disease in the emergency setting De Simone B, Davies J, Chouillard E, et al. · World journal of emergency surgery : WJES · 2021 · Clinical guideline DOIPubMed 33971899Full text
  32. Incidence of SARS-CoV-2 infection in inflammatory bowel disease Lee MH, Ng CH, Chin YH, et al. · Journal of gastroenterology and hepatology · 2020 · Meta-analysis DOIPubMed 32779774Full text
  33. Ulcerative Colitis-Diagnostic and Therapeutic Algorithms Kucharzik T, Koletzko S, Kannengiesser K, et al. · Deutsches Arzteblatt international · 2020 · Meta-analysis DOIPubMed 33148393Full text
  34. The association between endometriosis and autoimmune diseases: a systematic review and meta-analysis Shigesi N, Kvaskoff M, Kirtley S, et al. · Human reproduction update · 2019 · Meta-analysis DOIPubMed 31260048Full text
  35. ACG Clinical Guideline: Ulcerative Colitis in Adults Rubin DT, Ananthakrishnan AN, Siegel CA, et al. · The American journal of gastroenterology · 2019 · Clinical guideline DOIPubMed 30840605
  36. ACG Clinical Guideline: Management of Crohn's Disease in Adults Lichtenstein GR, Loftus EV, Isaacs KL, et al. · The American journal of gastroenterology · 2018 · Clinical guideline DOIPubMed 29610508
  37. Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition Turner D, Ruemmele FM, Orlanski-Meyer E, et al. · Journal of pediatric gastroenterology and nutrition · 2018 · Clinical guideline DOIPubMed 30044357
  38. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease de Lange KM, Moutsianas L, Lee JC, et al. · Nature genetics · 2017 · Meta-analysis DOIPubMed 28067908Full text
  39. Inflammatory bowel disease and risk of stroke: A meta-analysis of cohort studies Yuan M, Zhou HY, Xiao XL, et al. · International journal of cardiology · 2016 · Meta-analysis DOIPubMed 26386936
  40. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS Menees SB, Powell C, Kurlander J, et al. · The American journal of gastroenterology · 2015 · Meta-analysis DOIPubMed 25732419

Din il-paġna ġiet tradotta awtomatikament mill-Ingliż. Il-citazzjonijiet u n-numri mhumiex mibdula. Aqra l-original Ingliż jekk xi ħaġa taqra b'mod stramb. Aqra l-original Ingliż